A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer.

Song, Li; Yu, Wenbin; Xie, Fei; Liu, Zhimin; Lv, Weiwei; Shi, Duan-Bo; Yu, Dexin; Wang, Meng; Wang, Hua; Zhao, Yongtian; Chen, Cheng; Zhao, Zhikun; Gao, Jing; Sheng, Lei; Liu, Lian

doi:10.1200/jco.2021.39.15_suppl.4061

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The original search identified a total of 602 publications, and the study retrieval process is depicted in Figure 1. Twenty studies met the inclusion criteria, including a total number of 753 patients, were included in this meta-analysis (17,(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38). Of these, 15 studies reported that patients received neoadjuvant immunotherapy combined with chemotherapy, which our meta-analysis mainly focused on.…”

Section: Resultsmentioning

confidence: 99%

“…Several studies have illustrated that the addition of radiotherapy ( 28 , 30 ) or anti-VEGF drugs ( 20 , 29 ) improved the effectiveness of neoadjuvant therapy. Our study reported that, compared with the addition of radiotherapy or anti-VEGF drugs with single neoadjuvant immunochemotherapy, the combination with radiotherapy did improve MPR rate but had a higher incidence of TRAEs.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have shown promising prospects in locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) immunotherapy, but their efficacy in neoadjuvant settings remains unclear. This study aimed to assess the efficacy and safety of integrating programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors into neoadjuvant chemotherapy (NACT) of GC/GEJC treatment.MethodsPubMed, Cochrane Library, Embase, ClinicalTrials.gov, and main oncology conference databases were systematically searched up to 19 November 2022, and randomized controlled trials (RCTs) and cohort studies that evaluated the efficacy and safety of PD-1/PD-L1 inhibitors plus NACT were included. The main outcomes were pathological complete response (pCR), major pathological response (MPR), R0 resection rate, and treatment-related adverse events (TRAEs).ResultsA total of 753 patients from 20 prospective studies were included in this meta-analysis. The pooled pCR and MPR rates from studies reporting were 21.7% [95% confidence interval (CI), 18.1%–25.5%] and 44.0% (95% CI, 34.1%–53.8%), respectively. The pooled incidence rate of total TRAEs was 89.1% (95% CI, 82.7%–94.3%), and the incidence rate of grade 3 to 4 TRAEs was 34.4% (95% CI, 17.8%–66.5%). The pooled R0 resection rate was reported to be 98.9% (95% CI, 97.0%–99.9%). Subgroup analysis has not found significant differences in efficacy and safety among different PD-1/PD-L1 inhibitors. Moreover, the efficacy in patients with positive PD-L1 expression (combined positive score ≥1) was comparable with that in the entire study population [pCR, 22.5% vs. 21.2% (p > 0.05); MPR, 48.6% vs. 43.7% (p > 0.05)].ConclusionThis systematic review and meta-analysis found that PD-1/PD-L1 inhibitors combined with NACT for locally advanced GC/GEJC were well tolerated and may confer therapeutic advantages. The integration of ICIs into NACT has shown the potential for application in any PD-L1 expression population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Following a median observation period of 26.7 months, 55.6% (5/9) of the patients undergoing radical resection were free of recurrence. Notably, there were no reported complications of grade 3 or higher ( Li et al, 2021 ).…”

Section: Application Of Icis In the Perioperative Settingmentioning

confidence: 93%

Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer

Lin,

Chen,

Huang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Gastric/gastroesophageal junction (G/GEJ) cancer represents a significant global health challenge. Radical surgery remains the cornerstone of treatment for resectable G/GEJ cancer. Supported by robust evidence from multiple clinical studies, therapeutic approaches, including adjuvant chemotherapy or chemoradiation, and perioperative chemotherapy, are generally recommended to reduce the risk of recurrence and enhance long-term survival outcomes post-surgery. In recent years, immune checkpoint inhibitors (ICIs) have altered the landscape of systemic treatment for advanced or metastatic G/GEJ cancer, becoming the standard first-line therapy for specific patients. Consequently, exploring the efficacy of ICIs in the adjuvant or neoadjuvant setting for resectable G/GEJ cancer is worthwhile. This review summarizes the current advances in the application of ICIs for resectable G/GEJ cancer.

show abstract

“…Lian Lu et al recently confirmed the efficacy of a combination of camrelizumab, an IgG4κ humanized monoclonal antibody (mAb), anti-angiogenics, and chemotherapy for neoadjuvant/conversion treatment of cT4a/bN + gastric cancer [47]. Patients received camrelizumab (200 mg d1), apatinib (250 mg d1-14), S-1 (50 mg bid d1-10) ± oxaliplatin (85 mg/m 2 ) for at least two cycles, followed by re-evaluation and operation.…”

Section: Ongoing Clinical Trialsmentioning

confidence: 97%

Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials

Hispán

Pedregal

Cristóbal

et al. 2021

JCM

View full text Add to dashboard Cite

Peritoneal metastases from gastric cancer play a key role in the fatal prognosis of the disease. The lack of efficacy of actual therapeutic approaches together with the outcomes achieved with checkpoint inhibitors in gastric cancer compel us to address the current state-of-the-art immunotherapy treatment of peritoneal dissemination. The immunogenicity of the peritoneum has been described to be particularly active at omentum and peritoneal lymph nodes. Also, both innate and acquired immunity seems to be involved at different molecular levels. Recent works show PDL1 expression being less present at the peritoneal level; however, some clinical trials have begun to yield results. For example, the ATTRACTION-2 trial has demonstrated the activity of Nivolumab in heavily pretreated patients even though peritoneal metastases were diagnosed in a 30% of them. Despite positive results in the metastatic setting, peritoneal responses to systemic checkpoint inhibitors remains unclear, therefore, new strategies for intraperitoneal immunotherapy are being proposed for different ongoing clinical trials.

show abstract

A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer.

Cited by 8 publications

References 0 publications

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer

Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials

Contact Info

Product

Resources

About